UFC Ultimate Fighter 7 alumni CB Dollaway hasn’t competed since a second round TKO loss to Khalid Murtazaliev at UFC Fight Night Moscow. It is going to be awhile before Dollaway competes again because the fighter has accepted a two year suspension from the United States Anti-Doping Agency (USADA).
The infractions against Dollaway include a positive test for multiple banned substances and a banned rehydration method.
USADA issued the following press release on the matter:
August 26, 2019
USADA announced today that CB Dollaway of Gilbert, Ariz., has accepted a two-year sanction for a violation of the UFC Anti-Doping Policy after testing positive for multiple prohibited substances and using a prohibited method.
Dollaway, 35, tested positive for anastrozole, growth hormone releasing peptide 2 (GHRP-2 or pralmorelin), a metabolite of GHRP-2, and GHRP-6 as the result of an out-of-competition urine sample he provided on December 19, 2018. Anastrozole is a Specified Substance in the class of Hormone and Metabolic Modulators, while GHRP-2 and GHRP-6 are Specified Substances in the class of Peptide Hormones, Growth Factors, Related Substances and Mimetics. All of these substances are prohibited at all times under the UFC Anti-Doping Policy, which has adopted the World Anti-Doping Agency (WADA) Prohibited List.
Dollaway also tested positive for clomiphene in an out-of-competition urine sample collected on February 9, 2019. Clomiphene is a Specified Substance in the category of Hormone and Metabolic Modulators and is prohibited at all times under the UFC Anti-Doping Policy.
Additionally, Dollaway received an over-the-limit intravenous (IV) infusion on December 13, 2018. IV infusions and/or injections of more than 100 mL per 12-hour period are prohibited, except for those legitimately received in the course of hospital treatments, surgical procedures, or clinical diagnostic investigations.
Dollaway’s two positive tests and use of an over-the-limit IV were treated as a single, first violation because, after a thorough investigation, it was determined that the positive tests were consistent with ingestion prior to January 11, 2019, the date he received notification of his first positive test. Dollaway’s two-year period of ineligibility began on December 13, 2018.
USADA conducts the year-round, independent anti-doping program for all UFC athletes. USADA is an independent, non-profit, non-governmental agency whose sole mission is to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. In an effort to aid UFC athletes, as well as their support team members, in understanding the rules applicable to them, USADA provides comprehensive instruction on the UFC Anti-Doping Program website (https://UFC.USADA.org) regarding the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.
In addition, the agency manages a drug reference hotline, Drug Reference Online (https://UFC.GlobalDRO.com), conducts educational sessions, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, and periodic athlete alerts. Many of the resources available to athletes are provided in multiple languages, including Russian, Spanish, French, Portuguese, Korean, and Japanese.
Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at playclean @usada.org, by phone at 1 877-Play Clean (1-877-752-9253), or by mail.
Dolloway, who can return to action on December 13 of 2020, issued the following statement through Instagram: